Cardiac, neuroadrenergic, and portal hemodynamic effects of prolonged aldosterone blockade in postviral Child A cirrhosis

American Journal of Gastroenterology

Volumn 100, Issue 5, 2005, Pages 1110-1116

  Pozzi, Massimo ^a   Grassi, Guido ^b   Ratti, Laura ^b   Favini, Giorgio ^b   Dell'Oro, Raffaella ^b   Redaelli, Elena ^b   Calchera, Ivan ^b   Boari, Giuseppe ^b   Mancia, Giuseppe ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; CANRENOIC ACID; CANRENOATE POTASSIUM;

ADULT; ARTICLE; ASCITES; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLE; ECHOCARDIOGRAPHY; ESOPHAGUS VARICES; FEMALE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE HYPERTROPHY; HEMODYNAMICS; HUMAN; LIVER CIRRHOSIS; LIVER HEMODYNAMICS; LIVER VENOUS PRESSURE GRADIENT; LONG TERM CARE; MALE; MUSCLE SYMPATHETIC NERVE ACTIVITY; NEUROADRENERGIC HEMODYNAMICS; NEUROGRAPHY; PERONEUS NERVE; PORTAL HEMODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; STRUCTURE ACTIVITY RELATION; SYMPATHETIC TONE; VENOUS PRESSURE; ADRENERGIC NERVE; CASE CONTROL STUDY; COMPARATIVE STUDY; DRUG EFFECT; HEART; HEART STROKE VOLUME; HEART VENTRICLE; HEPATITIS B; HEPATITIS C; LIVER CIRCULATION; LIVER VEIN; LONGITUDINAL STUDY; MIDDLE AGED; PATHOPHYSIOLOGY; PORTAL VEIN; VIROLOGY;

ADRENERGIC FIBERS; ALDOSTERONE ANTAGONISTS; CANRENOATE POTASSIUM; CASE-CONTROL STUDIES; DIASTOLE; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; HEART; HEART VENTRICLES; HEMODYNAMIC PROCESSES; HEPATIC VEINS; HEPATITIS B; HEPATITIS C; HUMANS; LIVER CIRCULATION; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PERONEAL NERVE; PORTAL SYSTEM; STROKE VOLUME; VENOUS PRESSURE;

EID: 19144369614     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.41060.x     Document Type: Article

References (38)

1. Bernardi M, Trevisani F. Systemic and regional hemodynamics in preascitic cirrhosis. J Hepatol 1997;27:588-91.
2. Pozzi M, Carugo S, Boari G, et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997;26:1131-7.
3. Wong F, Liu P, Lilly L, et al. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci 1999;97:259-67.
4. Blendis L, Wong F. Is there a cirrhotic cardiomyopathy? Am J Gastroenterol 2000;95:3026-7.
5. De Franchis R. Updating consensus in portal hypertension: Report of the Baveno III Consensus workshop on definition, methodology and therapeutic strategies in portal hypertension. J Hepatol 2000;33:846-52.
6. Pozzi M, Grassi G, Redaelli E, et al. Patterns of regional sympathetic nerve traffic in preascitic and ascitic cirrhosis. Hepatology 2001;34:1113-8.
7. Moller S, Henriksen JH. Cardiovascular dysfunction in cirrhosis: Pathophysiological evidence of a cirrhotic cardiomyopathy. Scand J Gastroenterol 2001;36(8):785-94.
8. Garcia-Pagan JC. Primary prophylaxis. In: De Franchis R, eds. Portal Hypertension III: Proceedings of the third Baveno International consensus workshop on definition, methodology and therapeutic strategies. Oxford: Blackwell Science Ltd, 2001:127-33.
9. Willet IR, Esler M, Jennings J, et al. Sympathetic tone modulates portal venous pressure in alcoholic cirrhosis. Lancet 1986;2:939-43.
10. Tage-Jensen U, Henriksen JH, Christensen E, et al. Plasma catecholamine level and portal pressure as guides to prognosis in patients with cirrhosis. J Hepatol 1988;6:350-8.
11. Henricksen JH, Moller S, Ring-larsen H, et al. The sympathetic nervous system in liver disease. J Hepatol 1998;29:328-41.
12. Bernardi M, Di Marco C, Trevisani F, et al. Renal sodium retention during upright posture in preascitic cirrhosis. Gastroenterology 1993;105:188-93.
13. Brilla CG, Matsubara L, Weber KT. Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol 1993;71:12A-6A.
14. Wang W. Chronic administration of aldosterone depressess barorereceptor reflex function in the dog. Hypertension 1994;24:571-5.
15. Grassi G. Aldosterone: A hormone with adverse autonomic effects? Clin Sci 1998;95:647-8.
16. Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-65.
17. Grassi G, Bolla GB, Seravalle G, et al. Comparison between sensitivity of muscle sympathetic nerve traffic and plasma noradrenaline in man. Clin Sci 1997;92:285-9.
18. Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens 1999;17:719-34.
19. Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
20. Armonis A, Patch D, Burroughs A. Hepatic venous pressure measurement: An old test as a new prognostic marker in cirrhosis? Hepatology 1997;25:245-8.
21. Perello A, Escorsell A, Bru C, et al. Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus-related cirrhosis. Hepatology 1999;30:1393-7.
22. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms Recommendations for Quantitations of the Left Ventricle by Two-Dimensional Echocardiography. J Am Soc Echocardiogr 1989;2:631-7.
23. Kupari M, Koskinen P. Systolic flow velocity profile in the left ventricular outflow tract in persons free of heart disease. Am J Cardiol 1993;72:1172-8.
24. Triulzi MO, Castini D, Ornaghi M, et al. Effects of preload reduction on mitral flow velocity pattern in normal subjects. Am J Cardiol 1990;66:995-1001.
25. Devereux RB, Reichek N. Echocardiographic determination of the left ventricular mass in man. Anatomic validation of the method. Circulation 1997;55:613-8.
26. Zoli M, Merkel C, Magalotti D, et al. Natural history of cirrhotic patients with small esophageal varices: A prospective study. Am J Gastroenterol 2000;95:503-8.
27. Klein CP. Spironolactone in the treatment of portal hypertension in liver cirrhosis. A new therapeutic principle? Dtsch Med Wochenschr 1985;110:1774-6.
28. Okumura H, Aramaki T, Katsuta Y, et al. Reduction in hepatic venous pressure gradient as a consequence of volume contraction due to chronic administration of spironolactone in patients with cirrhosis and no ascites. Am J Gastroenterol 1991;86:46-52.
29. Garcia-Pagàn JC, Salmeron JM, Feu F, et al. Effect of low sodium diet and spironolactone on portal in patients with compensated cirrhosis. Hepatology 1994;19:1095-9.
30. Sugano S, Kawafune T, Okajima T, et al. Chronic splanchnic hemodynamic effects of spironolactone with unrestricted sodium diet in patients with compensated cirrhosis. Dig Dis Sci 1998;43:893-7.
31. Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol 2003;38(S1):54-68.
32. Mancia G, Mark AL. Arterial baroreflex in humans. In: Shepherd JT, Abboud FM, eds. Handbook of physiology: The cardiovascular system. Vol III. Bethesda, MD: American Physiology Society, 1983:755-95.
33. Mark AL, Mancia G. Cardiopulmonary reflex in humans. In: Shepherd JT, Abboud FM, eds. Handbook of physiology: The cardiovascular system. Vol II. Bethesda, MD: American Physiology Society 1983:795-813.
34. Bernardi M, Calandra S, Colantoni A, et al. Q-T interval prolongation in cirrhosis: Prevalence, relationship with severity, and etiology of the disease and possible pathoaenetic factors. Hepatology 1998;27:28-34.
35. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30-4.
36. Katsuta Y, Aramaki T, Sekiyama T, et al. Plasma volume contraction in portal hypertension. J Hepatol 1993;17(S2):S19-23.
37. La Villa G, Barletta G, Romanelli RG, et al. Cardiovascular effects of canrenone in patients with preascitic cirrhosis. Hepatology 2002;35:1441-8.
38. Abecasis R, Kravetz D, Fassio E, et al. Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic patients: A preliminary study. Hepatology 2003;37:359-65.